Icatibant is a peptidomimetic drug serving as a bradykinin-receptor antagonist and is approved in Europe and the United States for the treatment of hereditary angioedema attacks. We have detected an impurity with a high structural similarity to icatibant in pharmaceutical dosage forms using an optimized chromatographic method based on reversed phase high performance liquid chromatography with UV detection. The abundance of the impurity was around 1% relative to the icatibant peak following storage at room temperature for 1 month, and raised up to~16% upon temperature stressing at 100°C. The impurity was isolated by fraction collection and further purified by solid phase extraction for structural identification. NMR and high resolution mass spectrometric analyses revealed that this impurity results from isomerization in the N-terminal single amino acid residue. The new impurity may warrant particular attention due to its exceptional similarity to the active ingredient icatibant.
Introduction
Icatibant (also known as HOE 140) is an active pharmaceutical ingredient acting as a bradykinin-receptor antagonist (Hock et al., 1991; Cicardi et al., 2010) , and was consistently shown to be well-tolerated and effective in the treatment of hereditary angioedema (HAE) attacks (Lumry et al., 2011; Bork et al., 2007; Malbrán et al., 2014) . It is known under the trade name Firazyr® and received approval by the European commission in 2008 and by the FDA in 2011. Hereditary angioedema is a condition caused by C1 esterase inhibitor deficiency and usually results from a genetic defect transmitted as an autosomal dominant trait (Zuraw, 2008) . The condition was first described by William Osler in 1888 (Osler, 1888) and is characterized by recurrent episodes of edema that affects the arms, legs, face, intestinal tract, and airway and has a prevalence of approximately one in 50,000 people (Nzeako et al., 2001) . If left without treatment it results into death through airway obstruction in 25% of patients (Landerman, 1962) .
Icatibant belongs structurally to a class of drugs called peptidomimetics (Fig. 1) . Peptide drugs are gaining increasing popularity as their complex peptide structure confers these drugs exceptional target specificity and therefore high potency with relatively few off-target side effects compared to low molecular weight (< 500 Da) drugs (Craik et al., 2013; Fosgerau and Hoffmann, 2015; Sachdeva, 2017) . On the other hand this high complexity in their chemical structure seriously confounds their analysis and characterization (D'hondt et al., 2014) . In particular, the steric purity of these drugs poses a great challenge as an alteration in the conformation of a single or a few amino acids is unlikely to result into significant change in the physicochemical properties and may easily go undetected (D'hondt et al., 2014) . Therefore, there is a constant need for highly optimized isolation and analytical quality control methods. Ermer et al. proposed a novel approach for the quality control analysis of peptide drugs, taking icatibant as an example, based on the digestion of the peptide and then analyzing the chiral impurity of the resulting individual amino acids compared with a chirally pure standard (Ermer et al., 1995) . The proposed approach can be effective in assessing the general steric purity of peptide drugs but does not obviate the need for more specific approaches.
In the present work we report the chromatographic separation and the elucidation of the chemical structure of an unknown major impurity with a very high structural similarity to icatibant. Furthermore, we report a forced degradation study to investigate the formation of this impurity. The aim of the present work is to draw the attention of the pharmaceutical community to this impurity due to its very similar chromatographic behavior relative to the active pharmaceutical ingredient.
Materials and methods
The study is based on the icatibant finished pharmaceutical product prepared by Fresenius Kabi Austria GmbH (Graz, Austria) and submitted to the FDA for approval (submission number ANDA 208317) as well as on the original pharmaceutical product Firazyr® (Shire, Jersey). The formulation of the finished product (Fresenius Kabi Austria GmbH, Graz, Austria), which is based on the original pharmaceutical product Firazyr® (Shire, Jersey), is composed of icatibant acetate (30 mg icatibant), 22.72 mg sodium chloride, 4.03 mg glacial acetic acid, and 1.95 mg sodium hydroxide for adjustment to pH 5.5, and water for injection up to 3.0 mL. The pure active pharmaceutical ingredient (stated purity 81.7%) was obtained from BCN peptides (Barcelona, Spain). For standard preparation as well as the dilution of the pharmaceutical formulation, we used a solution prepared by dissolving 5.3 g of diammonium hydrogen phosphate in 1000 mL deionized water with pH 4.0 adjusted with phosphoric acid 85% (Sigma-Aldrich, Germany).
A chromatographic method was developed in order to separate the active pharmaceutical ingredient icatibant from its impurities in the prepared solutions. This was performed using an Agilent 1260 HPLC system (Agilent Technologies, Waldbronn, Germany) equipped with a diode array UV detector using an XBridge Peptide C18 BEH column (250 × 4.6 mm, 3.5 μm, 130 Å, Waters Milford, Massachusetts, USA). The mobile phase consisted of mobile phase A which was prepared by dissolving 5.3 g diammonium hydrogen phosphate (Sigma-Aldrich, Germany) in 1000 mL ultrapure water (18.2 MΩ cm, obtained from a Millipore Milli-Q reference ultrapure water purification system, USA), with pH 1.2 adjusted with 85% phosphoric acid, and mobile phase B which contained 90% acetonitrile (gradient grade; VWR International, UK) and 10% ultrapure water (v/v). A gradient with the following settings was used: 100% A at 0.0 min; 91.0% A at 5.0 min; 85.0% at 8.0 min; 76.5% A at 25.0 min; 40.0% A at 32.0 min; 40.0% A at 34.0 min; 100% A at 34.1 min; 100% A at 40 min. The autosampler was kept at 8°C, the injection volume was 1.0 μL, the column temperature was set at 75°C, and the detection was performed using UV absorption wavelength of 200 nm. The samples were filled in 0.7 mL polypropylene vials (Bruckner Analysentecknik, Linz, Austria) before injection into the HPLC system. Both icatibant and the icatibant impurity which elutes at a relative retention 0.99 (Fig. 2) were fractionated after chromatographic separation of a temperature stressed pharmaceutical formulation (1 month at 25°C followed by 100°C for 3 days) using the chromatographic method described above, except of an increased injection volume of 20 μL, using an Agilent 1100 HPLC system equipped with a variable wavelength UV detector and a fraction collector. The collected fractions were combined (total of 210 injections; ca. 70 mL) and desalted and pre-concentrated for NMR and high resolution mass spectrometric analyses. This was performed by solid phase extraction (SPE) using IST Isolute C18 (EC) cartridges (500 mg sorbent, 3 mL, Biotage, Uppsala, Sweden) with a SUPELCO VISIPREPTM SPE manifold connected to a membrane pump. The solid phase extraction was performed as follows: the cartridges were conditioned with 3.0 mL methanol then 3.0 mL ultrapure water. The fractions were loaded and two washing steps were applied using 3.0 mL ultrapure water and 1.0 mL of 20 mM ammonium formate, respectively. For elution, 1 mL of a solution of 20 mM ammonium formate containing 50% acetonitrile (v/v) was used. The eluent was frozen at −80°C in a 15 mL polypropylene tube and freeze-dried. The dry residue was stored at 4°C until analysis by NMR or mass spectrometry.
For the mass spectrometric identification we used a Dionex Ultimate 3000 UHPLC system (Thermo Scientific, Waltham, USA) connected to a Q-Exactive Orbitrap mass spectrometer equipped with electrospray ionization source (Thermo Scientific, Waltham, USA). MS/MS experiments were performed in positive mode, with a drying gas temperature of 400°C and a spray voltage of 3.5 kV. The full MS scan range was set to 200-1350 m/z at a resolution of 70,000 (full width at half maximum (FWHM), specified at m/z 200) with data-depending MS/MS. The fragmentation with normalized collision energy of 33.3 was performed at a resolution of 17,500 (FWHM). The mass accuracy of the measurements was < 5 ppm. The chromatographic separation was performed using a Zorbax SB-C18 column (2.1 × 50 mm; 1.8 μm, Agilent Technologies, Waldbronn, Germany), using a mobile phase A 17.5% (0.1% formic acid in acetonitrile) and mobile phase B 82.5% (0.1% formic acid in ultrapure water). The flow rate was 0.3 mL min
, and the column temperature was 50°C.
The NMR analyses were performed on the purified freeze-dried fractions (see above) which were reconstituted in 500 μL of a mixture ultrapure water containing 10% D 2 O. The experiments were performed at room temperature using a Bruker Avance III 700 MHz NMR spectrometer (Bruker, Billerica, Massachusetts, US) using a 5 mm cryogenically cooled TXI probe equipped with z-axis gradients. Spectral assignment was achieved using 1D 1H and 13C as well as 2D TOCSY, HSQC and HMBC spectra.
Results and discussion
The most closely related impurity of icatibant in the analyzed pharmaceutical formulation (stored at 60°C for 4 weeks) in terms of chromatographic properties was found to be eluting at a relative retention time (RRT) of 0.99 relative to the icatibant signal at~23 min (Fig. 2) . We performed stress tests on the finished pharmaceutical dosage form under different conditions and found a considerable increase in the abundance of this impurity (from 1% up to 16% upon high temperature stressing at 100°C) relative to the total peak area (see Supplementary material S1 table + Fig. S1 ). This suggests that this impurity is likely to be a common degradation product of icatibant that could arise upon temperature stressing. Elevated temperatures showed a tremendous formation of this impurity, whereas oxidative, acid and base stress did not result in a significant increase (see Table S1 ).
The developed chromatographic method achieved a resolution of 1.3 between the investigated impurity and icatibant peaks, and was subjected to thorough robustness testing including variation in conditions such as pH, buffer concentration, flow rate, organic solvent composition, column temperature, gradient settings, and column batch (for examples see Supplementary material S2).
It was possible to obtain a clean fraction and purify the impurity at RRT 0.99 by fraction collection as described in the experimental section (> 90% purity based on peak areas, supplementary material S3). The purified fraction was reinjected before as well as after solid phase extraction in order to check the success of fraction collection and to ensure the integrity of the purified impurity throughout the sample preparation steps.
The Orbitrap high resolution mass spectrometry experiments revealed an identical exact mass for the impurity at RRT 0.99 to icatibant and an identical fragmentation MS/MS data (supplementary material S4), indicating that the difference in the chemical structure between icatibant and the impurity in question might be in the steric Fig. 1 . Chemical structure of icatibant. B. Lajin, et al. European Journal of Pharmaceutical Sciences 132 (2019) 121-124 conformation of the composing amino acids. Indeed, a series of NMR experiments revealed very small differences except for a chemical shift in the alpha hydrogen of the N-terminal arginine residue (number 1 in Fig. 1 ). Based on the interpretation of the NMR data we proposed a structure similar to icatibant but with an L-arginine residue in place of D-arginine in the N-terminus of the peptide. We confirmed this assignment by using a synthesized compound with the proposed structure (obtained from BCN peptides, Barcelona, Spain), which showed an identical HSQC NMR spectrum to the isolated impurity (Supplementary material Fig. S5 ). It is noteworthy that the impurity RRT 0.99 was also found in the original pharmaceutical product Firazyr® (Shire, Jersey) and was identified by an independent team in the Fresenius Kabi Research and Innovation department. They used a similar experimental approach for the isolation and characterization of the impurity, but prepared the acetate salt to ensure a better NMR comparison. Therefore, shift differences caused by the counter ion could be avoided. The forced degradation resulting in an increase of the impurity with RRT 0.99 was achieved by autoclaving at 121°C. Ultimately, their experiments resulted in the same structural assignment of impurity RRT 0.99 as L-Arg (1) icatibant (Supplementary material Fig. S6 ).
Impurity generation through isomerization in peptide products is a well-studied topic, and the underlying chemical mechanisms have been characterized (Palasek et al., 2007; Souza et al., 2004; Angell et al., 2002) . However, it is difficult to predict how the change in the steric conformation of the N-terminal amino acid arginine would influence the biological activity or toxicological profile of icatibant. There are only very few examples describing the consequences of isomerization in a peptide drug. Finder et al. reported an increased aggregation rate for the recombinant amyloid β-peptide relative to the synthetic peptide, and explained this difference by racemization in three amino acid residues, namely, histidine, arginine, and methionine in the synthetic product (Finder et al., 2010) .
Isomerization poses a major challenge in quality control of peptide drugs. Most of the official methods for peptide drug analysis in the United States Pharmacopeia rely on HPLC-UV involving chromatographic columns based on silica with C18 (L1) or, less commonly C8 bonding (L7), and resin based ion-exchange (L9), which have limited ability to detect steric changes in single amino acid residues given the size and complexity of the structure of peptide drugs. In order to address this problem, it is possible to digest the peptide drug into the individual amino acids by chemical hydrolysis and analyze the composition of the individual chiral amino acids (Ermer et al., 1995) . Ermer et al. indicated that absolute measurement of the individual chiral amino acids is complicated by the fact that the chemical hydrolysis process can be accompanied by racemization of the amino acid residues. Therefore, the total content would not specifically reflect the intrinsic chiral composition of the peptide (Ermer et al., 1995) . An alternative approach depending on relative comparison with a chirally pure peptide with known chiral composition was proposed (Ermer et al., 1995) . When applying this approach on icatibant, Ermer et al. noted a slight decrease in the total percentage of D-Arginine of the total Arginine upon temperature stressing (from 33.1 (unstressed) to 33.0 (3 days at 37°C) to 32.9% (14 days at 37°C)). This decrease is small but in line with the formation of the impurity described in the present report containing L-arginine in place of D-arginine.
Conclusion
A new diastereomeric impurity for icatibant was identified and chromatographically separated from the active pharmaceutical ingredient. This impurity exhibits very similar chromatographic properties to icatibant and is another example of the challenge of racemization in the continuously growing peptidomimetic drugs market. To ensure product quality we recommend selectivity testing of the chromatography by using an API with altered chirality on C-and/or N-terminal amino acids.
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